Nemolizumab Found to Be Effective in Atopic Dermatitis

Share this content:
Nemolizumab Found to Be Effective in Atopic Dermatitis
Nemolizumab Found to Be Effective in Atopic Dermatitis

FRIDAY, March 3, 2017 (HealthDay News) -- An experimental drug, nemolizumab, may significantly reduce the itching and improve the appearance of moderate-to-severe atopic dermatitis, according to a study published in the March 2 issue of the New England Journal of Medicine.

In this 12-week trial, a team lead by Thomas Ruzicka, M.D., of Ludwig Maximilian University in Munich, randomly assigned 264 patients with moderate-to-severe atopic dermatitis to one of three injectable doses of nemolizumab (a humanized antibody against interleukin-31 receptor A) or placebo.

The researchers found that those who received nemolizumab every four weeks had significant improvement in their atopic dermatitis, compared with patients who received a placebo. Among the 216 patients who completed the study, those getting the second-highest dose of nemolizumab, which the researchers considered to have the best effect with the lowest risk, experienced a 59.8 percent reduction in itching, compared with a 20.9 percent reduction among patients who received a placebo.

In addition, patients receiving the second-highest dose of the drug saw a 42.3 percent reduction in the size of the areas of atopic dermatitis, compared with a 26.6 percent reduction among those receiving a placebo. Patients getting that dose also had a 20.0 percent reduction in the total body area affected by atopic dermatitis, compared with a 15.7 percent reduction among those receiving placebo. Seventeen percent of participants withdrew from the study because of side effects, which included worsening atopic dermatitis, respiratory tract infections, infections of the nose or throat, or swelling of the ankles or feet.

The study was funded by Tokyo-based Chugai Pharmaceutical, the manufacturer of nemolizumab.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »